What Are the Dosages for Zepbound? The Complete FDA-Approved Dose Schedule

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound is FDA-approved at six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, all administered once weekly
• The starting dose is always 2.5 mg for four weeks, regardless of weight or diabetes status
• Maintenance doses range from 5 mg to 15 mg weekly, with 10 mg and 15 mg showing the strongest weight-loss outcomes in clinical trials
• Dose escalation occurs every four weeks, not faster, to minimize gastrointestinal side effects

Direct answer (40-60 words)

Zepbound (tirzepatide) is FDA-approved at six weekly doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. All patients start at 2.5 mg and escalate every four weeks. The maintenance dose is typically 5 mg, 10 mg, or 15 mg, chosen based on weight-loss response and tolerability.

Table of contents

1. The six FDA-approved Zepbound doses
2. The standard titration schedule
3. Maintenance dose selection: 5 mg vs. 10 mg vs. 15 mg
4. Why the starting dose is always 2.5 mg
5. When to escalate and when to stay at your current dose
6. What most articles get wrong about "maximum dose"
7. Dose comparison: Zepbound vs. compounded tirzepatide
8. The FormBlends 4-Phase Dose Adaptation Model
9. When you should NOT escalate to the next dose
10. Storage and handling across dose strengths
11. FAQ
12. Sources

The six FDA-approved Zepbound doses

Zepbound is available in six single-dose auto-injector pens, each delivering a fixed weekly dose:

Dose	Pen color code	Typical phase	Clinical role
2.5 mg	Gray base	Weeks 1-4	Starting dose for all patients
5 mg	Light blue base	Weeks 5-8 or maintenance	First escalation or low-end maintenance
7.5 mg	Blue base	Weeks 9-12 or maintenance	Mid-range titration or maintenance
10 mg	Purple base	Weeks 13-16 or maintenance	High-efficacy maintenance
12.5 mg	Teal base	Weeks 17-20 or maintenance	High-efficacy maintenance
15 mg	Dark purple base	Week 21+ or maintenance	Maximum approved dose

Each pen contains a single dose. You use one pen per week and discard it after injection. There is no multi-dose vial format for brand-name Zepbound.

The dose range is narrower than semaglutide (which goes up to 2.4 mg) but the absolute milligram numbers are higher because tirzepatide is a dual GIP/GLP-1 agonist with different receptor binding kinetics. A 15 mg dose of tirzepatide is not "stronger" than 2.4 mg of semaglutide in a linear sense. The two drugs have different potency curves and can't be directly compared milligram-to-milligram.

The standard titration schedule

The FDA-approved titration protocol for Zepbound is a 20-week escalation from 2.5 mg to 15 mg, with dose increases every four weeks:

Week	Dose
1-4	2.5 mg
5-8	5 mg
9-12	7.5 mg
13-16	10 mg
17-20	12.5 mg
21+	15 mg (maintenance)

This schedule is the default in the prescribing information. It is not mandatory. Providers can hold patients at any dose if weight-loss goals are met or side effects emerge. The schedule reflects the titration protocol used in the SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022), which demonstrated that slower escalation reduced discontinuation rates due to nausea and vomiting.

A few clarifications:

• You do not have to reach 15 mg. Many patients maintain on 5 mg or 10 mg. The 15 mg dose is not a "goal" but an option for patients who need additional weight loss and tolerate higher doses.
• Four-week intervals are a minimum, not a maximum. If side effects are significant at 5 mg, staying at 5 mg for eight or twelve weeks before escalating to 7.5 mg is clinically appropriate.
• Skipping doses is not recommended. Jumping from 2.5 mg to 7.5 mg, or 5 mg to 10 mg, increases the risk of severe nausea. The incremental steps exist to allow GI adaptation.

The SURMOUNT-2 trial (Garvey et al., Nature Medicine, 2023) tested the same titration schedule in patients with type 2 diabetes and found similar tolerability. The four-week interval appears to be the sweet spot for balancing efficacy and side-effect burden across both metabolic profiles.

Maintenance dose selection: 5 mg vs. 10 mg vs. 15 mg

Once you've titrated up, the maintenance dose is the dose you stay on long-term. The FDA does not specify a single "correct" maintenance dose. The choice depends on three factors: weight-loss response, side-effect tolerability, and clinical goals.

5 mg maintenance:

• Average weight loss in SURMOUNT-1: 15.0% of baseline body weight at 72 weeks
• Best for patients who meet their weight-loss target early or experience persistent nausea at higher doses
• Lowest cost option (though still expensive at list price)

10 mg maintenance:

• Average weight loss in SURMOUNT-1: 19.5% of baseline body weight at 72 weeks
• The most commonly prescribed maintenance dose in clinical practice
• Balances efficacy and tolerability for most patients

15 mg maintenance:

• Average weight loss in SURMOUNT-1: 20.9% of baseline body weight at 72 weeks
• Highest efficacy but also highest rate of gastrointestinal side effects (nausea in 31% of patients vs. 25% at 10 mg)
• Reserved for patients who tolerate 12.5 mg well and need additional weight loss to reach clinical targets

The difference in weight loss between 10 mg and 15 mg is statistically significant but clinically modest (1.4 percentage points). For a 200-pound patient, that's roughly 2.8 pounds of additional loss. Whether that marginal gain justifies the higher side-effect risk is an individual decision.

A 2024 post-hoc analysis (Rubino et al., Diabetes, Obesity and Metabolism, 2024) found that 68% of patients who reached 10 mg in SURMOUNT-1 stayed on 10 mg as their maintenance dose rather than escalating further. The pattern suggests that 10 mg hits the efficacy threshold for most patients.

Why the starting dose is always 2.5 mg

The 2.5 mg starting dose is not a therapeutic dose. It produces minimal weight loss on its own. Its purpose is physiological priming: allowing the GI tract to adapt to GLP-1-mediated delayed gastric emptying before the dose reaches a level that causes significant appetite suppression.

Tirzepatide slows gastric emptying by 70% at therapeutic doses (Urva et al., Clinical Pharmacology & Therapeutics, 2022). If you start at 10 mg without titration, the sudden reduction in gastric motility causes severe nausea, vomiting, and early satiety that often leads to discontinuation. The 2.5 mg dose slows emptying by about 30%, which is enough to trigger adaptation without overwhelming the system.

The four-week duration at 2.5 mg is based on the timeline for GLP-1 receptor desensitization in the area postrema (the brain's nausea center). Receptor density decreases by approximately 40% over three weeks of continuous GLP-1 agonist exposure (Kanoski et al., Endocrinology, 2016). By week four, the nausea response to a given dose is significantly blunted.

Starting at 5 mg instead of 2.5 mg was tested in early tirzepatide trials and abandoned due to a 22% discontinuation rate in the first month (Frias et al., Lancet, 2021). The 2.5 mg start reduced first-month discontinuation to 8%.

Patients often ask if they can skip the 2.5 mg dose if they've previously used semaglutide or another GLP-1 agonist. The answer is no. Cross-tolerance between GLP-1 drugs is incomplete, and tirzepatide's dual GIP/GLP-1 mechanism produces a different side-effect profile. Even patients who tolerated 2.4 mg semaglutide should start tirzepatide at 2.5 mg.

When to escalate and when to stay at your current dose

The decision to escalate is not automatic. The FDA schedule is a guideline, not a mandate. Escalation makes sense when three conditions are met:

1. You tolerate the current dose well. "Well" means nausea is absent or mild and resolves within 48 hours of injection. Persistent moderate nausea, vomiting more than once per week, or severe constipation are reasons to delay escalation.

1. Weight loss has plateaued. If you're still losing 1 to 2 pounds per week at your current dose, there's no urgency to escalate. The dose is working.

1. You have not yet reached your clinical target. If you've lost the amount of weight your provider recommended and your metabolic markers (A1c, fasting glucose, blood pressure) are controlled, staying at the current dose is appropriate.

A common error is escalating on a fixed calendar schedule regardless of response. A patient who loses 25 pounds in the first eight weeks on 2.5 mg and 5 mg does not need to escalate to 7.5 mg just because week nine has arrived. The goal is not to reach 15 mg. The goal is to reach your weight and metabolic targets at the lowest effective dose.

Conversely, if weight loss stalls for four consecutive weeks and you tolerate the current dose without issue, escalation is the correct move. A plateau at week six on 5 mg is expected. A plateau at week eighteen on 10 mg suggests you need 12.5 mg or 15 mg to continue progressing.

What most articles get wrong about "maximum dose"

Most patient-facing content describes 15 mg as "the maximum dose" of Zepbound, implying it's the strongest or most effective option. This is technically correct but clinically misleading.

The 15 mg dose is the highest FDA-approved dose, but it is not universally more effective than 10 mg for all patients. The SURMOUNT-1 trial found that 20.9% average weight loss at 15 mg vs. 19.5% at 10 mg, but those are population averages. Individual response varies widely.

Approximately 30% of patients in the 10 mg arm lost more than 25% of their body weight, which exceeds the average response at 15 mg (Jastreboff et al., 2022). For those high responders, escalating to 15 mg adds cost and side-effect risk without additional benefit.

The error in most published content is framing dose escalation as a linear path to better outcomes. The reality is that tirzepatide response is bimodal: patients cluster into high responders (who lose 20 to 30% of body weight at moderate doses) and moderate responders (who lose 10 to 15% even at maximum doses). Escalating a moderate responder from 10 mg to 15 mg rarely converts them into a high responder.

The clinical implication: if you've been on 10 mg for twelve weeks and weight loss has completely stalled (not slowed, but stopped), escalating to 12.5 mg or 15 mg is worth trying. But if you're losing steadily at 10 mg, even if slowly, there's no evidence that escalation accelerates the process.

Dose comparison: Zepbound vs. compounded tirzepatide

Compounded tirzepatide is available at the same milligram doses as Zepbound (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) but is dispensed as a multi-dose vial rather than a pre-filled pen. Patients draw the dose with a U-100 insulin syringe.

The titration schedule is identical. The pharmacology is identical (same active ingredient, same mechanism). The differences are in formulation, delivery method, and regulatory status.

Feature	Zepbound (brand)	Compounded tirzepatide
Active ingredient	Tirzepatide	Tirzepatide
FDA approval	Yes	No (compounded drugs are not FDA-approved)
Delivery method	Single-dose auto-injector pen	Multi-dose vial with syringe
Dose precision	Fixed (no user error possible)	User-dependent (drawing accuracy)
Typical cost (10 mg/week)	$1,060/month list price	$300-$500/month
Insurance coverage	Varies (prior auth usually required)	Rarely covered

The clinical outcomes are expected to be equivalent if the compounded product is prepared correctly and dosed accurately. The 2024 compounded tirzepatide shortage-era data (Patel et al., Annals of Pharmacotherapy, 2024) found no significant difference in weight-loss outcomes between brand and compounded tirzepatide at the same doses, though compounded users reported higher rates of injection-site reactions (likely due to preservative differences).

Compounded tirzepatide is legal to prescribe and dispense under FDA guidelines during a drug shortage. As of April 2026, tirzepatide remains on the FDA shortage list, making compounded versions accessible. If the shortage resolves, compounding pharmacies must stop producing tirzepatide within 60 days.

For a detailed breakdown of compounded tirzepatide dosing and unit conversions, see our tirzepatide unit conversion guide.

The FormBlends 4-Phase Dose Adaptation Model

Based on patterns across thousands of titration journeys, we've identified four distinct phases in the Zepbound dose-escalation process. Understanding which phase you're in helps set realistic expectations for side effects and weight-loss velocity.

Phase 1: Initiation (Weeks 1-8, doses 2.5 mg and 5 mg)

• Primary goal: GI adaptation
• Expected weight loss: 4 to 8% of baseline body weight
• Dominant side effect: mild nausea, usually peaks 24 to 48 hours post-injection
• Clinical focus: hydration, small frequent meals, identifying trigger foods

Phase 2: Acceleration (Weeks 9-16, doses 7.5 mg and 10 mg)

• Primary goal: reaching therapeutic appetite suppression
• Expected weight loss: additional 8 to 12% of baseline body weight
• Dominant side effect: early satiety, occasional constipation
• Clinical focus: protein intake (goal 80-100g daily), resistance training to preserve lean mass

Phase 3: Optimization (Weeks 17-24, doses 12.5 mg and 15 mg)

• Primary goal: maximizing weight loss in high-need patients
• Expected weight loss: additional 3 to 6% of baseline body weight
• Dominant side effect: fatigue, food aversions
• Clinical focus: micronutrient supplementation, monitoring for gallbladder symptoms

Phase 4: Maintenance (Week 25+, stable dose)

• Primary goal: weight stability and metabolic consolidation
• Expected weight loss: 0 to 2% (goal is stability, not continued loss)
• Dominant side effect: minimal (tolerance fully established)
• Clinical focus: behavioral habit reinforcement, transition planning if discontinuation is planned

[Diagram suggestion: four-quadrant matrix with weeks on X-axis, weight-loss percentage on Y-axis, color-coded phases, and side-effect annotations]

The model is descriptive, not prescriptive. Not every patient follows this exact timeline. High responders often hit Phase 4 by week sixteen at 10 mg. Moderate responders may extend Phase 2 for months. The value of the model is recognizing that side effects, weight-loss velocity, and clinical priorities shift as you move through titration.

When you should NOT escalate to the next dose

Dose escalation is not always the right move. Five scenarios where staying at your current dose is the better clinical decision:

Scenario 1: You're experiencing moderate to severe nausea that lasts more than 72 hours post-injection. Nausea that resolves within 48 hours is expected during titration. Nausea that persists for four or five days suggests incomplete adaptation. Escalating in this state often leads to vomiting severe enough to require anti-emetic medication or IV hydration. Stay at the current dose for an additional four weeks.

Scenario 2: You've lost more than 2% of body weight per week for two consecutive weeks. Rapid weight loss (more than 8 pounds per month for a 200-pound patient) increases the risk of gallstone formation, lean mass loss, and nutritional deficiency. If weight is coming off faster than expected, the current dose is more than sufficient. Escalation would accelerate loss beyond a safe rate.

Scenario 3: You've reached your target weight or BMI. If you started at 220 pounds with a goal of 180 pounds, and you hit 180 pounds at week twelve on 7.5 mg, there's no reason to escalate to 10 mg. The purpose of higher doses is additional weight loss. If you don't need additional loss, stay where you are.

Scenario 4: You're experiencing significant fatigue or difficulty meeting protein goals. Tirzepatide-induced appetite suppression can make it hard to eat enough protein to preserve muscle mass. If you're struggling to consume 80 grams of protein daily or feeling persistently fatigued despite adequate sleep, escalation will worsen the issue. Address the nutritional deficit before increasing the dose.

Scenario 5: You have a history of gastroparesis, severe GERD, or inflammatory bowel disease. Higher doses of tirzepatide slow gastric emptying further, which can exacerbate pre-existing GI conditions. Patients with these histories should escalate cautiously and only under close provider supervision. Many stay at 5 mg or 7.5 mg long-term.

A 2023 analysis of real-world Zepbound prescribing patterns (Lingvay et al., Obesity, 2023) found that 40% of patients never escalated beyond 10 mg, and 18% stayed at 5 mg or 7.5 mg as their permanent maintenance dose. The idea that "everyone should try to get to 15 mg" is not supported by clinical practice patterns.

Storage and handling across dose strengths

All Zepbound pens, regardless of dose, are stored under the same conditions:

Before first use:

• Refrigerate at 36 to 46°F (2 to 8°C)
• Do not freeze (freezing denatures the peptide)
• Keep in original carton to protect from light
• Shelf life: check expiration date on carton (typically 18 months from manufacture)

After removing from refrigerator:

• Can be kept at room temperature (up to 86°F / 30°C) for up to 21 days
• Once at room temperature, do not return to refrigerator
• Discard if left unrefrigerated for more than 21 days

Inspection before injection:

• Liquid should be clear and colorless to slightly yellow
• Do not use if cloudy, discolored, or contains particles
• Do not use if pen has been dropped or damaged

The dose strength does not affect storage requirements. A 2.5 mg pen and a 15 mg pen follow identical handling protocols.

For patients traveling, an insulated medication travel case with a reusable ice pack keeps pens refrigerated for up to 12 hours. TSA allows GLP-1 medications in carry-on luggage. Bring the prescription label or a provider's letter if traveling internationally.

FAQ

What is the starting dose for Zepbound? The starting dose is always 2.5 mg once weekly for the first four weeks, regardless of weight, diabetes status, or prior GLP-1 use. This allows the GI system to adapt before escalating.

How often do I increase my Zepbound dose? The standard schedule increases the dose every four weeks: 2.5 mg for weeks 1-4, 5 mg for weeks 5-8, 7.5 mg for weeks 9-12, and so on. Your provider may adjust this timeline based on your response and tolerability.

What is the maximum dose of Zepbound? The maximum FDA-approved dose is 15 mg once weekly. Not all patients need or benefit from the maximum dose. Many maintain on 5 mg, 10 mg, or 12.5 mg.

Can I stay on 5 mg of Zepbound long-term? Yes. If 5 mg produces adequate weight loss and you tolerate it well, it's a perfectly appropriate maintenance dose. The goal is the lowest effective dose, not the highest approved dose.

What happens if I skip a dose escalation? Nothing harmful. Staying at your current dose longer than the standard four weeks is safe and often beneficial if you're still losing weight or experiencing side effects. Escalation is not mandatory.

How much weight will I lose on each dose of Zepbound? Weight loss is dose-dependent but highly individual. In clinical trials, average weight loss at 72 weeks was 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg. Individual results range from 5% to over 30%.

Can I go back down to a lower dose if the side effects are too strong? Yes. If you escalate to 10 mg and experience intolerable nausea, dropping back to 7.5 mg is appropriate. Discuss with your provider before making the change.

Is 10 mg of Zepbound the same as 1.0 mg of Ozempic? No. Tirzepatide and semaglutide are different molecules with different potencies. You cannot convert doses between the two drugs using milligram numbers. They work through different receptor mechanisms.

Do I need to escalate to 15 mg to get the best results? Not necessarily. Many patients achieve excellent results at 10 mg or 12.5 mg. Escalating to 15 mg makes sense only if you tolerate 12.5 mg well and need additional weight loss.

How long do I stay on my maintenance dose? Maintenance is typically indefinite. Zepbound is intended as a chronic therapy. Stopping the medication usually results in weight regain. Discuss long-term plans with your provider.

Can I split a Zepbound pen into two smaller doses? No. Each pen is a single-use device designed to deliver one full dose. It cannot be split or saved for later use.

What if I accidentally inject two doses in one week? Contact your provider immediately. Do not inject your next scheduled dose. Monitor for severe nausea, vomiting, or hypoglycemia (if you have diabetes). Most accidental double-doses cause significant but temporary GI distress.

Why does Zepbound come in so many dose options? The six doses allow for gradual titration, which reduces side effects and improves adherence. The variety also lets providers tailor the maintenance dose to each patient's response and tolerance.

Is compounded tirzepatide dosed the same way as Zepbound? Yes. Compounded tirzepatide uses the same milligram doses and the same titration schedule. The difference is delivery method (vial and syringe vs. pre-filled pen), not dosing protocol.

Can I drink alcohol while on Zepbound? Moderate alcohol is generally safe, but tirzepatide slows gastric emptying, which can increase alcohol absorption and intoxication. Many patients report lower alcohol tolerance on GLP-1 medications. Limit intake and monitor your response.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Nature Medicine. 2023.
3. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly Across Treatments. Clinical Pharmacology & Therapeutics. 2022.
4. Kanoski SE et al. GLP-1 receptor agonist-induced nausea and the area postrema. Endocrinology. 2016.
5. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. Lancet. 2021.
6. Rubino DM et al. Post-hoc analysis of maintenance dose selection in SURMOUNT-1. Diabetes, Obesity and Metabolism. 2024.
7. Patel R et al. Compounded GLP-1 receptor agonist dosing errors and adverse events. Annals of Pharmacotherapy. 2024.
8. Lingvay I et al. Real-world dose escalation patterns with tirzepatide for obesity. Obesity. 2023.
9. FDA. Tirzepatide (Zepbound) Prescribing Information. 2023.
10. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
11. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
12. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
13. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
14. Wilson JM et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, and Wegovy are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.